Abbonarsi

METHODS OF GENE DELIVERY - 09/09/11

Doi : 10.1016/S0889-8588(05)70004-6 
Nelson A. Wivel, MD a, James M. Wilson, MD, PhD a, b
a Institute for Human Gene Therapy (NAW, JMW); Department of Molecular and Cellular Engineering (NAW, JMW) 
b Division of Medical Genetics (JMW); and Wistar Institute (JMW), University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 

Riassunto

With the continuing refinement of recombinant DNA techniques, the concept of human gene therapy has moved from a theoretic axis to the actual transfer of genes into the somatic cells of patients.20 The concept itself is rather straightforward and involves the insertion of genes into cells for the expressed intent of correcting an inborn genetic error or creating a new cellular function. In such a context, DNA has the potential to become the “drug” of choice.

There are two general categories of gene delivery systems, or vectors as they are commonly called: viral and nonviral vectors. Of the 210 gene therapy protocols that have been approved for phase I clinical trials, approximately 80% utilize virus vectors.37 Despite the fact that virally derived vectors have many of the characteristics of the parent viruses themselves, and despite the fact that some of these viruses may be pathogens in their normal state, it remains that viruses have evolved a number of very efficient mechanisms to assure that replication occurs. One of the most important characteristics is the ability of the virus to assure transport of its genomic DNA to the nucleus of the host cell without degradation by lysosomes.45 It has become clear that one can take advantage of some of the barriers to gene expression by using viruses as the delivery vehicles, and this is discussed in more detail later.

Included among the nonviral vector systems are direct DNA delivery, liposomes, and DNA–protein complexes. Each of these systems has certain kinds of advantages. For example, such vectors can be more easily prepared in a uniform fashion and can be made in relatively unlimited quantities; almost none of these compounds invoke an inflammatory response. A number of factors, however, may contribute to a reduced efficiency of expression. There may be competitive uptake by cells of the reticuloendothelial system when such cells are not the target cells of choice, and some types of liposomes are subject to nonspecific binding by a large range of different cell types.

Currently, all of the available delivery systems, both viral and nonviral, suffer specific types of shortcomings. Yet there are abundant data to indicate that such systems can be successfully manipulated by changing surface recognition components, deleting certain structural genes, or inserting transcriptional elements that favor gene expression in certain restricted target cells.32 A description of the major vector systems, both in use and in development, is the subject of this discussion.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 Address reprint requests to Nelson A. Wivel, MD, University of Pennsylvania, School of Medicine, M1 Maloney Building, 36th and Spruce Streets, Philadelphia, PA 19104–4283


© 1998  W. B. Saunders Company. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 12 - N° 3

P. 483-501 - giugno 1998 Ritorno al numero
Articolo precedente Articolo precedente
  • PREFACE
  • STEPHEN L. ECK
| Articolo seguente Articolo seguente
  • GENETIC MODIFICATION OF THE HEMATOLYMPHOID COMPARTMENT FOR THERAPEUTIC PURPOSES
  • William G. Kerr

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.